Literature DB >> 25365092

The development of the disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28).

P L C M van Riel1.   

Abstract

In rheumatoid arthritis, disease activity cannot be measured using a single variable. The Disease Activity Score (DAS) has been developed as a quantitative index to be able to measure, study and manage disease activity in RA in daily clinical practice, clinical trials, and long term observational studies. The DAS is a continuous measure of RA disease activity that combines information from swollen joints, tender joints, acute phase response and patient self-report of general health. Cut points were developed to classify patients in remission, as well as low, moderate, and severe disease activity in the 1990s. DAS-based EULAR response criteria were primarily developed to be used in clinical trials to classify individual patients as non-, moderate, or good responders, depending on the magnitude of change and absolute level of disease activity at the conclusion of the test.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25365092

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  41 in total

1.  Analysis of Programmed Death-1 in Patients with Psoriatic Arthritis.

Authors:  Michael Peled; Marianne Strazza; Inbar Azoulay-Alfaguter; Gregg J Silverman; Jose U Scher; Adam Mor
Journal:  Inflammation       Date:  2015-08       Impact factor: 4.092

2.  Comparison between different disease activity scores in rheumatoid arthritis: an Egyptian multicenter study.

Authors:  M Eissa; A El Shafey; M Hammad
Journal:  Clin Rheumatol       Date:  2017-05-22       Impact factor: 2.980

3.  Influence of the different "patient global assessment" formulations on disease activity score by different indices in rheumatoid arthritis.

Authors:  Ricardo J O Ferreira; Gisela Eugénio; Mwidimi Ndosi; Cristiana Silva; Catarina Medeiros; Cátia Duarte; J A P da Silva
Journal:  Clin Rheumatol       Date:  2018-03-10       Impact factor: 2.980

4.  Clinical effectiveness and safety of leflunomide in inflammatory arthritis: a report from the RAPPORT database with supporting patient survey.

Authors:  Morgan Schultz; Stephanie O Keeling; Steven J Katz; Walter P Maksymowych; Dean T Eurich; Jill J Hall
Journal:  Clin Rheumatol       Date:  2017-05-27       Impact factor: 2.980

5.  Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratio as predictors of 12-week treatment response and drug persistence of anti-tumor necrosis factor-α agents in patients with rheumatoid arthritis: a retrospective chart review analysis.

Authors:  Han-Na Lee; Yun-Kyung Kim; Geun-Tae Kim; Eunyoung Ahn; Min Wook So; Dong Hyun Sohn; Seung-Geun Lee
Journal:  Rheumatol Int       Date:  2019-03-14       Impact factor: 2.631

6.  New Inflammatory Marker Associated with Disease Activity in Rheumatoid Arthritis: The Systemic Immune-Inflammation Index.

Authors:  Serap Satis
Journal:  Curr Health Sci J       Date:  2021-12-31

7.  The genetics of rheumatoid arthritis: new insights and implications.

Authors:  David T Felson; Lars Klareskog
Journal:  JAMA       Date:  2015-04-28       Impact factor: 56.272

8.  Patient-reported outcome instruments for assessing Raynaud's phenomenon in systemic sclerosis: A SCTC Vascular Working Group Report.

Authors:  John D Pauling; Tracy M Frech; Michael Hughes; Jessica K Gordon; Robyn T Domsic; Marina E Anderson; Francesca Ingegnoli; Neil J McHugh; Sindhu R Johnson; Marie Hudson; Francesco Boin; Voon H Ong; Marco Matucci-Cerinic; Nezam Altorok; Marina Scolnik; Mandana Nikpour; Ankoor Shah; Janet E Pope; Dinesh Khanna; Ariane L Herrick
Journal:  J Scleroderma Relat Disord       Date:  2018-05-24

Review 9.  Advances and challenges in hemophilic arthropathy.

Authors:  Tine Wyseure; Laurent O Mosnier; Annette von Drygalski
Journal:  Semin Hematol       Date:  2015-10-26       Impact factor: 3.851

10.  Intra- and Interrater Reliability and Concurrent Validity of a New Tool for Assessment of Breast Cancer-Related Lymphedema of the Upper Extremity.

Authors:  Bryan Spinelli; Michael J Kallan; Xiaochen Zhang; Andrea Cheville; Andrea Troxel; Joy Cohn; Lorraine Dean; Kathleen Sturgeon; Margaret Evangelista; Zi Zhang; David Ebaugh; Kathryn H Schmitz
Journal:  Arch Phys Med Rehabil       Date:  2018-10-04       Impact factor: 3.966

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.